You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌礼(01672.HK)续涨31%创逾七个月高 旗下药品被使用作新型肺炎临床试验
阿思达克 02-03 11:53

歌礼制药(01672.HK)旗下药品被使用作新型肺炎临床试验,该股承上周五急涨25%强势,今早突破牛熊线(5.04元),最多再飙近57%高见6.5元,创逾七个月高,现造5.44元,续升31%,成交已达7,697万股,涉资4.2亿元。

歌礼公布,已收到相关医疗机构和研究人员申请使用公司研发ASC09复方片和利托那韦(Ritonavir)开展新型冠状病毒(2019-nCoV)感染患者临床试验;且河南省卫健委於1月31日宣布已有3例确诊新型冠状病毒感染患者在服用洛匹那韦╱利托那韦等药品後治癒。公司补充,利托那韦及ASC09复方片均为公司尚未获得上市批文的产品。公司已於2020年1月25日向国家药品监督管理局及其药品审评中心申请将利托那韦及ASC09复方片纳入国家应急通道。相关药监部门已确认收到公司该等申请。歌礼制药指,无法担保公司能取得利托那韦及ASC09复方片上市批准或最终成功地营销利托那韦及ASC09复方片。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account